More complex drug supply chains have increased the prevalence of counterfeit drugs around the globe in recent years.
Those seeking to counterfeit drugs now have multiple opportunities from the raw source material phase to a finished product to send fake or less effective pharmaceuticals to consumers or medical providers. Between 2005 and 2010 worldwide sales of counterfeit medicines rose 90% to $75 billion.
This year's most publicized case involved fake versions of Avastin, an injectable cancer drug ...